Fennec Pharmaceuticals Inc. (FENC) — Financial statements
Income statement, balance sheet, and cash flow for Fennec Pharmaceuticals Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 45↓6.1% | 48↑123.7% | 21↑1341.6% | 1 | 0.00 | |
| Cost of Revenue | 4↑18.2% | 3↑152.9% | 1↑1424.4% | 0.08 | 0.00 | |
| Gross Profit | 41↓7.8% | 44↑121.8% | 20↑1336.7% | 1 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.25↓18.6% | 0.31↑448.2% | 0.06↓98.3% | 3↓31.3% | 5 | |
| General & Administrative Expenses | 28↑22.7% | 23↑12.0% | 21 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 19↑1.0% | 18↑52.0% | 12 | 0.00 | 0.00 | |
| SG&A Expenses | 47↑13.1% | 41↑26.8% | 33↑66.1% | 20↑62.3% | 12 | |
| Other Expenses | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 47↑13.0% | 42↑27.5% | 33↑41.9% | 23↑35.2% | 17 | |
| Total Costs & Expenses | 51↑13.4% | 45↑32.2% | 34↑46.9% | 23↑35.7% | 17 | |
| Operating Results | ||||||
| Operating Income | -6↓347.1% | 3↑120.1% | -13↑41.1% | -22↓27.1% | -17 | |
| Depreciation & Amortization | 0.10↓87.1% | 0.80↑178.7% | 0.29 | 0.00 | 0.00 | |
| EBITDA | -7↓255.3% | 5↑138.8% | -12↑43.0% | -22↓27.1% | -17 | |
| EBIT | -8↓289.0% | 4↑131.6% | -13↑41.7% | -22↓27.1% | -17 | |
| Interest & Other Income | ||||||
| Net Interest Income | -1↑47.8% | -2↑16.2% | -3↓277.1% | -0.78↓987.5% | -0.07 | |
| Interest Income | 0.79↓50.6% | 2↑261.2% | 0.44↑126.2% | 0.20↑261.1% | 0.05 | |
| Interest Expense | 2↓48.9% | 4↑19.9% | 3↑247.0% | 0.98↑676.2% | 0.13 | |
| Non-Operating Income | 1↑184.5% | -1↓1091.7% | -0.12↓6155.5% | -0.00↑35.5% | -0.00 | |
| Other Income / Expenses | -3↓24.6% | -3↑19.4% | -3↓203.0% | -1↓786.2% | -0.12 | |
| Income Before Tax | -10↓13470.4% | -0.07↑99.6% | -16↑29.5% | -23↓32.5% | -17 | |
| Income Tax Expense | 0.11↓71.0% | 0.37 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -10↓2134.2% | -0.44↑97.3% | -16↑29.5% | -23↓32.5% | -17 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -10↓2134.2% | -0.44↑97.3% | -16↑29.5% | -23↓32.5% | -17 | |
| Bottom-Line Net Income | -10↓2134.2% | -0.44↑97.3% | -16↑29.5% | -23↓32.5% | -17 | |
| EPS (Basic) | -0.36↓2150.0% | -0.02↑97.3% | -0.60↑36.8% | -0.95↓41.8% | -0.67 | |
| EPS (Diluted) | -0.36↓2150.0% | -0.02↑97.3% | -0.60↑36.8% | -0.95↓41.8% | -0.67 | |
| Weighted Average Shares | 29↑4.7% | 27↑2.7% | 27↑1.1% | 26↑1.0% | 26 | |
| Weighted Average Diluted Shares | 29↑4.7% | 27↑2.7% | 27↑1.1% | 26↑1.0% | 26 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.